These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 33974998)

  • 21. Phosphorothioate modification of chimeric 2´-O-methyl RNA/ethylene-bridged nucleic acid oligonucleotides increases dystrophin exon 45 skipping capability and reduces cytotoxicity.
    Malueka RG; Dwianingsih EK; Yagi M; Lee T; Nishida A; Iijima K; Takeshima Y; Matsuo M
    Kobe J Med Sci; 2015 Feb; 60(4):E86-94. PubMed ID: 25791417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model.
    Echevarría L; Aupy P; Relizani K; Bestetti T; Griffith G; Blandel F; Komisarski M; Haeberli A; Svinartchouk F; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Jun; 29(3):148-160. PubMed ID: 31009315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides.
    Hori SI; Mitsuoka Y; Kugimiya A
    Nucleic Acid Ther; 2019 Feb; 29(1):44-50. PubMed ID: 30508397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development.
    Tang SJ; Shen H; An O; Hong H; Li J; Song Y; Han J; Tay DJT; Ng VHE; Bellido Molias F; Leong KW; Pitcheshwar P; Yang H; Chen L
    Nat Commun; 2020 Feb; 11(1):799. PubMed ID: 32034135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligonucleotide repress telomerase activity via manipulating alternative splicing or translation.
    Zhou J; Li T; Geng X; Sui L; Wang F
    Biochem Biophys Res Commun; 2021 Dec; 582():118-124. PubMed ID: 34710826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antizyme inhibitor 1: a potential carcinogenic molecule.
    Qiu S; Liu J; Xing F
    Cancer Sci; 2017 Feb; 108(2):163-169. PubMed ID: 27870265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Alternative Splicing for Therapeutic Interventions.
    Centa JL; Hastings ML
    Methods Mol Biol; 2022; 2537():21-36. PubMed ID: 35895256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.
    Emmrich S; Wang W; John K; Li W; Pützer BM
    Mol Cancer; 2009 Aug; 8():61. PubMed ID: 19671150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy.
    Marchesi E; Cortesi R; Preti L; Rimessi P; Sguizzato M; Bovolenta M; Perrone D
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.
    Dewaele M; Tabaglio T; Willekens K; Bezzi M; Teo SX; Low DH; Koh CM; Rambow F; Fiers M; Rogiers A; Radaelli E; Al-Haddawi M; Tan SY; Hermans E; Amant F; Yan H; Lakshmanan M; Koumar RC; Lim ST; Derheimer FA; Campbell RM; Bonday Z; Tergaonkar V; Shackleton M; Blattner C; Marine JC; Guccione E
    J Clin Invest; 2016 Jan; 126(1):68-84. PubMed ID: 26595814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancer.
    Hong H; An O; Chan THM; Ng VHE; Kwok HS; Lin JS; Qi L; Han J; Tay DJT; Tang SJ; Yang H; Song Y; Bellido Molias F; Tenen DG; Chen L
    Nucleic Acids Res; 2018 Sep; 46(15):7953-7969. PubMed ID: 29796672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity.
    Ramírez-Moya J; Baker AR; Slack FJ; Santisteban P
    Oncogene; 2020 Apr; 39(18):3738-3753. PubMed ID: 32157211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
    Nakano M; Fukami T; Gotoh S; Nakajima M
    J Biol Chem; 2017 Mar; 292(12):4873-4884. PubMed ID: 28188287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysferlin Exon 32 Skipping in Patient Cells.
    Barthélémy F; Courrier S; Lévy N; Krahn M; Bartoli M
    Methods Mol Biol; 2018; 1828():489-496. PubMed ID: 30171562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
    Hwang J; Yokota T
    Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Antisense Oligonucleotide against a Splicing Enhancer Sequence within Exon 1 of the
    Maeta K; Farea M; Nishio H; Matsuo M
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
    Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
    PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.